Showing results (71-80 of 366) with videos related to

Sort By:
Pageof 37
Clinical Kidney Journal|July 5, 2021
Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experienceDiana Oleas, Mónica Bolufer, Irene Agraz, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 26, 2022
New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical OncologyDolores Isla, Maria D Lozano, Luis Paz-Ares, et al.
Human Molecular Genetics|August 20, 2004
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancerMiquel Taron, Rafael Rosell, Enriqueta Felip, et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|July 12, 2020
[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology]Fernando López-Ríos, Luis Paz-Ares, Julián Sanz, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2024
Treating cancer-associated venous thromboembolism: A practical approachEric Van Cutsem, Isabelle Mahé, Enriqueta Felip, et al.
Cancer Investigation|March 29, 2017
Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07Nuria Viñolas, Pilar Garrido, Dolores Isla, et al.
European Journal of Cancer Care|October 3, 2018
Lung cancer in Spanish women: The WORLD07 projectPilar Garrido, Nuria Viñolas, Dolores Isla, et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|April 15, 2023
[New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology]Dolores Isla, María D Lozano, Luis Paz-Ares, et al.
Future Oncology (London, England)|December 16, 2021
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancerByoung Chul Cho, Enriqueta Felip, Hidetoshi Hayashi, et al.
Pageof 37